GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Debt-to-EBITDA

Laekna (HKSE:02105) Debt-to-EBITDA : N/A (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Laekna's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$56.13 Mil. Laekna's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$5.54 Mil. Laekna's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Laekna's Debt-to-EBITDA or its related term are showing as below:

HKSE:02105' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.16   Med: -0.04   Max: -0.04
Current: -0.08

During the past 3 years, the highest Debt-to-EBITDA Ratio of Laekna was -0.04. The lowest was -0.16. And the median was -0.04.

HKSE:02105's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs HKSE:02105: -0.08

Laekna Debt-to-EBITDA Historical Data

The historical data trend for Laekna's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Debt-to-EBITDA Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.04 -0.04 -0.16

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA N/A - -0.03 -0.11 N/A

Competitive Comparison of Laekna's Debt-to-EBITDA

For the Biotechnology subindustry, Laekna's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Laekna's Debt-to-EBITDA falls into.



Laekna Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Laekna's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(56.129 + 5.544) / -395.679
=-0.16

Laekna's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(56.129 + 5.544) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Laekna  (HKSE:02105) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Laekna Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Laekna's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna (HKSE:02105) Business Description

Traded in Other Exchanges
N/A
Address
No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Liu Zeng 2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Liu Ying 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines